Regulation of aldehyde dehydrogenase activity in five rat hepatoma cell lines

• Published in: Cancer research (Baltimore) 1984-11, Vol.44 (11), p.5219-5226
• Main Authors: KWANG-HUEI LIN, WINTERS, A. L, LINDAHL, R
• Format: Article
• Language: English
• Subjects: Aldehyde Dehydrogenase - biosynthesis; Aldehyde Dehydrogenase - metabolism; Amanitins - pharmacology; Animal tumors. Experimental tumors; Animals; Benzo(a)pyrene - pharmacology; Biological and medical sciences; Cell Line; Cycloheximide - pharmacology; Dactinomycin - pharmacology; Enzyme Induction; Experimental digestive system and abdominal tumors; Kinetics; Liver Neoplasms, Experimental - enzymology; Medical sciences; Methylcholanthrene - pharmacology; Phenotype; Rats; Tumors
• ISSN: 0008-5472; 1538-7445

Significant changes in aldehyde dehydrogenase (ALDH) activity occur during rat hepatocarcinogenesis in vivo. An NADP-dependent tumor ALDH isozyme has been studied extensively. To better understand the nature, origin, and importance of this tumor-associated phenotypic change, we have examined the ALDH activity of five well-established rat hepatoma cell lines, H4-II-EC3, HTC, McA-RH7777, JM1, and JM2. HTC, JM1, and JM2 express the tumor ALDH phenotype, as indicated by elevated NADP-dependent, benzaldehyde-oxidizing activity, the appearance of new isozymes by electrophoresis, and characteristic histochemical localization of ALDH activity in situ. The tumor ALDH phenotype is not detected in McA-RH7777 cells. H4-II-EC3 has intermediate tumor ALDH activity. Thus, the 5 cell lines provide a spectrum of tumor ALDH activities representative of the range of activities seen in vivo. Benzo(a)pyrene, 3-methylcholanthrene, and phenobarbital induce hepatic ALDH activity after treatment in vivo. The ability of these compounds to induce ALDH in vitro was assessed in H4-II-EC3, McA-RH7777, HTC, JM1, and JM2. Treatment of cell cultures for 72 hr with 3-methylcholanthrene (1.0 mM) increases the NADP-dependent ALDH activity in H4-II-EC3 and McA-RH7777 cell lines up to 34- and 11-fold, respectively. Treatment with benzo(a)pyrene (1.0 mM) also increases the NADP-dependent ALDH activity in both lines up to 17- and 48-fold, respectively. Treatment with 3-methylcholanthrene or benzo(a)pyrene increases ALDH activity 2-fold in HTC and JM2 but does not increase NADP-dependent ALDH activity in JM1. Only marginal increases in NADP-dependent ALDH are observed after phenobarbital treatment in 4 of 5 cell lines. The induction of ALDH is blocked by actinomycin D, alpha-amanitin, and cycloheximide. These studies support our hypothesis that changes in ALDH activity observed in vivo are due to mutational events occurring in initiated cells. It appears that rat hepatoma cell lines will provide an in vitro model for studying genetic regulation of the tumor ALDH.